Evidence map›Paper›PMID 28704575›Full record

ReviewChemistry (Weinheim an der Bergstrasse, Germany)2017

Hema S Krishnan, Longle Ma, Neil Vasdev, Steven H Liang

Abstract readReview
In one paragraph

Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Radiosynthesis and Evaluation ofACS medicinal chemistry letters · 2026
    Article
  2. Article
  3. Article
  4. Imaging poly(ADP-ribose) polymerase-1 (PARP1)Acta pharmaceutica Sinica. B · 2025
    Article
  5. Development and Preclinical Characterization of [Journal of medicinal chemistry · 2025
    Article
  6. Radiosynthesis and Evaluation ofACS pharmacology & translational science · 2025
    Article
  7. Review
  8. Enhancing the Stability ofACS medicinal chemistry letters · 2025
    Article
  9. Development of a NovelACS pharmacology & translational science · 2025
    Article
  10. Development of a NovelMolecular pharmaceutics · 2025
    Article
  11. DLL3-targeted immunoPET and radioimmunotherapy ligands.American journal of nuclear medicine and molecular imaging · 2025
    Article
  12. Visualizing T-cell activation: PET imaging of CXCL9 as a window into the tumor immune response.American journal of nuclear medicine and molecular imaging · 2025
    Article
  13. Article
  14. Trop2-targeted immunoPET ligands.American journal of nuclear medicine and molecular imaging · 2025
    Article
  15. Article
  16. Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics.American journal of nuclear medicine and molecular imaging · 2025
    Article
  17. Simple and Efficient Synthesis ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Arginine-Selective Bioconjugation Reagent for EffectiveJournal of medicinal chemistry · 2024
    Article
  20. 7-[Journal of medicinal chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hema S KrishnanNuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Longle MaNuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Neil VasdevNuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.ORCID http://orcid.org/0000-0002-2087-5125
Steven H LiangNuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.ORCID http://orcid.org/0000-0003-1413-6315

Funding

Neuro-PET Radiotracer Discovery for Imaging Glycogen Synthase Kinase-3R01AG054473 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VASDEV, NEIL · 2017 to 2020
$1.7M
New PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927k
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR33DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2019 to 2021
$851k
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR21DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2017 to 2018
$425k
NIA NIH HHS R01 AG054473NIDA NIH HHS K01 DA038000NIDA NIH HHS R21 DA043507NIDA NIH HHS R33 DA043507
6 · The paper itself

Abstract

Positron emission tomography (PET) imaging study of fluorine-18 labeled biomolecules is an emerging and rapidly growing area for preclinical and clinical research. The present review focuses on recent advances in radiochemical methods for incorporating fluorine-18 into biomolecules via "direct" or "indirect" bioconjugation. Recently developed prosthetic groups and pre-targeting strategies, as well as representative examples in

Indexed as

Positron-Emission TomographyCycloaddition ReactionFluorine RadioisotopesHumansIsotope LabelingNucleotidesPeptidesRadiopharmaceuticalsSulfhydryl CompoundsFluorine-18Fluorine RadioisotopesNucleotidesPeptidesRadiopharmaceuticalsSulfhydryl Compoundsbioconjugationbiomoleculesclick chemistryfluorine-18positron emission tomography

Identifiers

PMID28704575
PMCPMC5675832

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.